Answer:
The transport of proteins and other bioactive materials from endoplasmic reticulum to the nucleus without the involvement of transport vesicles is the main beneficial for the cell to be continuous with the nuclear envelop.
Explanation:
The rough endoplasmic reticulum or RER that contain ribosomes on its surface is directly continuous with membrane of nucleus.
This helps nucleus to gain access to the proteins and other materials generated within endoplasmic reticulum.
If endoplasmic reticulum faces biological problems such as unfolded protein accumulation in the ER is hazardous to the cell.During such circumstances ER send specific signal to the nucleus.
The nucleus respond to that signal by reducing the rate of protein synthesis,so that the ER would get some extra time to fold the required proteins essential for cellular functioning,
<span>The option which is not a potential concern associated with the use of biotechnology is the production yields of GM foods, whereas the other options are quite dangerous when you think about them. Genetic ownership means that somebody could steal your genes and use them for cloning, which is another option here. Trainsgenic foods also have to be kept safe, so as to stop someone from messing with them. The production yields of GM foods is not the problem, the problem is whether that food is healthy or not.</span>
Marke me as brainliest please
it wont move at all because molecules want to be where there is most mass and that is the .5 salt so it will stay where it is at and not go into red blood cell
Answer:
D Natural selection
Explanation:
This is because the dominant Gene according to Charles Darwin is strong enough to adapt to any environment.Making it a survival of the fittest
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
